BPC-157
Also known as Body Protection Compound 157 · Pentadecapeptide BPC 157 · PL 14736
A 15-amino-acid peptide derived from a protein in human gastric juice, studied for gut-lining repair and soft-tissue healing.
Definition
BPC-157 (Body Protection Compound) is a synthetic fragment of a protein naturally present in human gastric juice. Its mechanism centres on VEGF-driven angiogenesis — promoting new blood-vessel growth at injury sites — and modulation of the nitric-oxide system. Clinically, it is used for chronic GI symptoms, IBD-adjacent inflammation, tendon and ligament repair, and as the adjunct most frequently prescribed to soften GLP-1 nausea during titration.
How Meto uses it.
BPC-157 is the single most-used peptide in the Meto catalogue. It is the backbone of the P1 GI Support Stack, is paired with TB-500 in the P3 Recovery Stack, and sits inside the RENEW formulation. Solo BPC-157 is not currently available while awaiting FDA regulatory action. Typical protocols run 4–12 weeks with either a loading-phase drop to PRN maintenance, or a cycled re-dose tied to symptom return. Oral capsules exist for gut-focused protocols; injected BPC-157 is standard for tendon, ligament and systemic repair.
Safety notes
- Contraindicated in active malignancy — the angiogenic mechanism would also support tumour growth
- Avoid in pregnancy and lactation
- Use with caution alongside anticoagulant therapy
- Prohibited under WADA rules for competition athletes
- Most-reported side effect: mild, transient injection-site redness
Not a complete list — your clinician reviews your full history, labs and medications during intake. Nothing here replaces that.
Common questions
Is BPC-157 FDA-approved?
No — it is prescribed as a compounded agent by FDA-registered 503A pharmacies under clinician supervision. HHS announced reclassification of ~14 peptides back to compounding-eligible status in early 2026; the FDA's advisory committee is reviewing BPC-157 and its peers in July 2026.
How fast does BPC-157 work?
For GI symptoms, most members see a drop in symptom scores within 7–14 days. For tendon and ligament repair, meaningful functional change is typically a 4–8 week window. If nothing has shifted by week 4, the clinician reconsiders the protocol.
Oral capsule vs. injection?
Oral is effective for gut-focused protocols because the peptide lands where it's working. For tendon, ligament or systemic repair, subcutaneous injection near the affected area is the clinically sensible route — and the protocol card specifies which.
Can BPC-157 help with my GLP-1 nausea?
It's the most common adjunct prescribed for this reason. By supporting mucosal integrity and modulating nitric oxide at the gut lining, BPC-157 can let members who had stalled on a low GLP-1 dose actually complete their titration.
Read More
VEGFVascular Endothelial Growth Factor
A signalling protein that drives the growth of new blood vessels — the primary mechanism behind BPC-157's tissue-repair effects.
MechanismNitric OxideNO
A signalling molecule that regulates blood flow and tissue repair — modulated by BPC-157 at the gut lining and injury sites.
MechanismAngiogenesis
The formation of new blood vessels from existing vasculature — the core repair mechanism BPC-157 accelerates via VEGF.
$149 panel.
A clinician reads it in 24 hours.
Order the Peptide Readiness Panel, draw at a Quest or LabCorp near you, and your clinician sends back a matched protocol with a confidence score.